Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Pregnancy, breastfeeding, certain thyroid-cancer histories, severe digestive conditions, and some medication combinations may make GLP-1 treatment unsuitable
Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on -cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis
The GPX7 gene is located on chromosome 1p32.3 and is composed of 4 exons that encode a 187 amino acid precursor protein
GLP-1 (Glucagon-like Peptide-1) is a natural incretin hormone that: Stimulates insulin secretion (when glucose is high) Suppresses glucagon release Slows gastric emptying Increases satiety reducing food intake Why GLP-1 Therapy Stands Out Glycemic Control Lowers HbA1c by ~11.5% with minimal hypoglycemia risk Weight Loss 515 kg depending on drug/dose (semaglutide leads the way) Cardiovascular Protection Reduced major CV events (MACE) in trials like LEADER, SUSTAIN, REWIND Renal Protection Slows progression of diabetic kidney disease Convenience Available as daily or weekly injections and even oral semaglutide Key Clinical Trials LEADER (Liraglutide) CV mortality & MACE SUSTAIN-6 (Semaglutide) CV events & strong weight loss REWIND (Dulaglutide) CV protection even in lower-risk populations STEP Trials (Semaglutide) Double-digit weight reduction in obesity The Bigger Picture GLP-1 therapy goes beyond insulin and beyond diabetes
US$ 27.44
US$ 26.58
US$ 22.26
US$ 25.29
US$ 22.88
US$ 23.31
US$ 28.01
